Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer
ChiCTR2600116027Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecapegfilgrastim in breast cancer and chemotherapy-induced neutropenia (CIN), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Incidence of febrile neutropenia (FN) across all chemotherapy cycles. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR2600116027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116027.